Shift From Adalimumab Originator to Biosimilars in Denmark.

Jensen, Thomas Bo

Shift From Adalimumab Originator to Biosimilars in Denmark. [electronic resource] - JAMA internal medicine 06 2020 - 902-903 p. digital

Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

2168-6114

10.1001/jamainternmed.2020.0338 doi


Adalimumab--economics
Adolescent
Adult
Anti-Inflammatory Agents--economics
Biosimilar Pharmaceuticals--economics
Child
Denmark
Drug Costs
Drug Substitution
Female
Humans
Male
Retrospective Studies
Young Adult